Syndax Pharmaceuticals: Promising Phase 2 Results Justify Buy …
1 day ago · Syndax Pharmaceuticals (SNDX) Company Description: Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat.
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage …
2 days ago · On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 ...
Syndax's Revumenib Trial Reports Positive Data In …
2 days ago · (RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 …
Nov 4, 2024 · WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo™ (axatilimab-csfr).
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy …
2 days ago · Syndax Pharmaceuticals (NASDAQ: SNDX) just reported positive results from the phase 2 portion of its AUGMENT-101m trial evaluating the use of Revumenib for the treatment of patients with relapsed ...
Syndax Announces Positive Pivotal Topline Results from Relapsed …
3 days ago · WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 …
Nov 4, 2024 · WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million ...
Royalty Pharma And Syndax Pharmaceuticals Enter Into $350 …
Nov 4, 2024 · Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company’s pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor.
Syndax Reports Third Quarter 2024 Financial Results and Provides ...
Nov 5, 2024 · 85,307,660. 69,645,888. Terms. Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its ...
Press Release Details - Syndax Pharmaceuticals, Inc.
Jun 6, 2024 · Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the CSF-1 receptor.
- Some results have been removed